AbbVie's Allergan Aesthetics Receives FDA Approval for Skinvive by Juvederm
On June 16, 2026, AbbVie Inc.'s subsidiary, Allergan Aesthetics, received U.S. Food and Drug Administration (FDA) approval for Skinvive by Juvederm to reduce neck lines in adults over the age of 21. This marks a significant milestone as it is the first hyaluronic acid injectable approved for this specific use.
Tickers: $ABBV
Topics: cosmetic_treatment pharmaceuticals